ArticleJournal of clinical microbiology2014
Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in clinical isolates by multiplex PCR.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.BMC infectious diseases · 2016Trial
- Expanding the scope of Mycobacterium abscessus reference strains to improve pulmonary disease modeling.Disease models & mechanisms · 2026Article
- Case Report:Frontiers in medicine · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- A post-surgical case of rib osteomyelitis and pleural abscess caused byOxford medical case reports · 2025Article
- Transposon-sequencing across multiplemBio · 2025Article
- Rapid identification of majorFrontiers in cellular and infection microbiology · 2025Article
- Article
- Identification of Mycobacterium abscessus using the peaks of ribosomal protein L29, L30 and hemophore-related protein by MALDI-MS proteotyping.Scientific reports · 2024Article
- Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin ofMicroorganisms · 2023Article
- Article
- A Systemic Lupus Erythematosus Patient with CutaneousAnnals of dermatology · 2023Article
- Addison's disease triggered by infection with mycobacterium abscessus, but not by adrenal tuberculosis or MAC pulmonary disease, in a subject with type 2 diabetes mellitus: case report.BMC endocrine disorders · 2022Article
- Potential Cross-Transmission of Mycobacterium abscessus among Non-Cystic Fibrosis Patients at a Tertiary Hospital in Japan.Microbiology spectrum · 2022Article
- The Use of Comparative Genomic Analysis for the Development of Subspecies-Specific PCR Assays forFrontiers in cellular and infection microbiology · 2022Article
- Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.Microbiology spectrum · 2021Article
- A first case report of nasopharyngeal Mycobacterium abscessus subspecies massiliense infection.European journal of medical research · 2021Article
- Peritoneal dialysis-associated peritonitis caused by Mycobacteroides massiliense: the first case and review of the literature.BMC nephrology · 2021Review
- A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility.EBioMedicine · 2021Article
- Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapidly growing mycobacterium M. abscessus sensu lato is the causative agent of emerging pulmonary and skin diseases and of infections following cosmetic surgery and postsurgical procedures. M. abscessus sensu lato can be divided into at least three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. Clinical isolates of rapidly growing mycobacteria were previously identified as M. abscessus by DNA-DNA hybridization. More than 30% of these 117 clinical isolates were differentiated as M. abscessus subsp. massiliense using combinations of multilocus genotyping analyses. A much more cost-effective technique to distinguish M. abscessus subsp. massiliense from M. abscessus subsp. abscessus, a multiplex PCR assay, was developed using the whole-genome sequence of M. abscessus subsp. massiliense JCM15300 as a reference. Several primer sets were designed for single PCR to discriminate between the strains based on amplicons of different sizes. Two of these single-PCR target sites were chosen for development of the multiplex PCR assay. Multiplex PCR was successful in distinguishing clinical isolates of M. abscessus subsp. massiliense from samples previously identified as M. abscessus. This approach, which spans whole-genome sequencing and clinical diagnosis, will facilitate the acquisition of more-precise information about bacterial genomes, aid in the choice of more relevant therapies, and promote the advancement of novel discrimination and differential diagnostic assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.